Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jgh.14994 This article is protected by copyright. All rights reserved. Poustchi Hossein (Orcid ID: 0000-0003-4566-3628) Merat Shahin (Orcid ID: 0000-0002-8088-6723) Hormati Ahmad (Orcid ID: 0000-0002-3942-0681) The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment SOF/DCV in Hepatitis C and Severe Renal Impairment Hossein Poustchi 1* , Sara Majd Jabbari 1* , Shahin Merat 1 , Amir-Houshang Sharifi 1 , Ali Akbar Shayesteh 2 , Elahe Shayesteh 2 , Mohammad Minakari 3 , Mohammad Reza Fattahi 4 , Maryam Moini 4 , Fatemeh Roozbeh 5 , Fariborz Mansour-Ghanaei 6 , Behrooz Afshar 7 , Marjan Mokhtare 8 , Taghi Amiriani 9 , Masoomeh Sofian 10 , Mohammad-Hossein Somi 11 , Shahram Agah 8 , Iradj Maleki 12 , Maryam Latifnia 13 , Mojtaba Fattahi Abdizadeh 14 , Ahmad Hormati 15,16 , Masoud Khoshnia 1,9 , Masoudreza Sohrabi 16 , Zeinab Malekzadeh 1 , Dorsa Merat 1 , Reza Malekzadeh 1 * HP and SMJ have contributed equally to this manuscript 1 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran; 2 Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 3 Isfahan University of Medical Sciences, Isfahan, Iran; 4 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 5 Mazandaran University of Medical Sciences, Sari, Iran; 6 Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran; 7 Hamadan University of Medical Sciences, Hamadan, Iran;